SCHEMBL5541540

SCHEMBL5541540

Cc1cocc1-c1ccccc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
MAPK1 P28482 3/20 0.41
MAOB P27338 4/20 0.41
MAOA P21397 3/20 0.41
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
TP53 P04637 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NFKB1 P19838 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
HSD11B1 P28845 2/20 0.36
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
MAPT P10636 2/20 0.33
TSHR P16473 2/20 0.33
HPGD P15428 1/20 0.33
MEN1 O00255 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541534 0.75 MAPK1 (0.41) ALDH1A1MAPK1MAOBMAOARAB9A
SCHEMBL3563744 0.75 ALDH1A1 (0.62) ALDH1A1MAPK1MAOBMAOARAB9A
SCHEMBL358976 0.74 ALDH1A1 (0.67) ALDH1A1MAPK1MAOBMAOARAB9A
SCHEMBL31295703 0.74 ALDH1A1 (0.67) ALDH1A1MAPK1MAOBMAOARAB9A
SCHEMBL17205088 0.71
SCHEMBL5546060 0.71 CYP2A6 (0.45) ALDH1A1MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL7519287 0.71 ALDH1A1 (0.63) ALDH1A1MAPK1MAOBMAOARAB9A
SCHEMBL31465796 0.71 ALDH1A1 (0.63) ALDH1A1MAPK1MAOBMAOARAB9A
SCHEMBL5545828 0.71 ALDH1A1 (0.38) ALDH1A1MAPK1MAOBMAOARAB9A
SCHEMBL8210892 0.70 ALDH1A1 (0.54) ALDH1A1MAPK1MAOBMAOARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885MAPK1 1392/4885MAOB 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.